Study guide
6.7: Infectious Disease Therapeutics & Antimicrobial Stewardship
Overseas Pharmacist Readiness Assessment OPRA
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1: About the OPRA Exam 1.2: Study and Preparation Strategy for OPRA
2 Chapter 2: Biomedical Sciences
2.1: Human Physiology & Homeostasis 2.2: Pathophysiology of Major Organ Systems 2.3: Medical Microbiology & Infectious Pathogens 2.4: Immunology & Immunotherapy 2.5: Body Fluids, Electrolytes, & Acid-Base Balance 2.6: Physiological Values & Clinical Lab Interpretations
3 Chapter 3: Medicinal Chemistry & Biopharmaceutics
3.1: Physicochemical Properties of Drugs 3.2: Biopharmaceutics & Formulation Science 3.3: Chemical Stability & Storage of Pharmaceuticals 3.4: Sterile Compounding & Pharmaceutical Microbiology
4 Chapter 4: Pharmacokinetics & Pharmacodynamics
4.1: Principles of Pharmacokinetics (Absorption & Distribution) 4.2: Drug Metabolism & Elimination Pathways 4.3: Quantitative Pharmacokinetics (Vd, Clearance, Half-life, Steady-state) 4.4: Clinical Pharmacokinetics (Dosing Adjustments & Non-linear Kinetics) 4.5: Pharmacodynamics & Receptor Theory
5 Chapter 5: Pharmacology & Toxicology
5.1: Mechanisms of Action: Cardiovascular & Renal Agents 5.2: Mechanisms of Action: Respiratory, CNS, & Endocrine Agents 5.3: Adverse Drug Reactions & Drug-Drug Interactions 5.4: Clinical Toxicology & Poisoning Management 5.5: Pharmacogenomics & Genetic Polymorphism
6 Chapter 6: Therapeutics & Patient Care
6.1: Pharmaceutical Calculations: Doses & Unit Conversions 6.2: Pharmaceutical Calculations: Infusions, Percentages, & Tonicity 6.3: Cardiovascular Therapeutics (Hypertension, Heart Failure, Dyslipidemia) 6.4: Anticoagulation & Antiplatelet Therapy 6.5: Endocrine & Metabolic Therapeutics (Diabetes & Thyroid) 6.6: Respiratory Therapeutics (Asthma & COPD) 6.7: Infectious Disease Therapeutics & Antimicrobial Stewardship 6.8: Central Nervous System & Mental Health Therapeutics 6.9: Gastrointestinal & Renal Therapeutics 6.10: Therapeutics in Special Populations: Pregnancy & Lactation 6.11: Therapeutics in Special Populations: Paediatrics & Geriatrics 6.12: Primary Health Care, Self-Care, & Harm Minimisation 6.13: Professional Practice, Ethics, & Communication
6.7: Infectious Disease Therapeutics & Antimicrobial Stewardship
Key Takeaways Explain This Topic AI
First-line empirical treatment for mild CAP is oral amoxicillin 1 g 8-hourly; severe CAP requires ceftriaxone 2 g IV daily plus azithromycin 500 mg IV daily.
First-line uncomplicated cystitis treatments include trimethoprim 300 mg daily for 3 days or nitrofurantoin 100 mg 6-hourly for 5 days (requires eGFR >= 30 mL/min).
Surgical prophylaxis standard agent is IV cephazolin 2 g (3 g if >120 kg) administered within 60 minutes prior to incision, with redosing after 4 hours or >1.5 L blood loss.
Antimicrobial stewardship tools include IV-to-oral switch (IVOS) criteria, requiring clinical improvement, defervescence (>24h), and functioning gastrointestinal tract.
Last updated: July 2026
6.7 Infectious Disease Therapeutics & Antimicrobial Stewardship
Infectious disease management in Australia is heavily guided by the Therapeutic Guidelines: Anti-infective (eTG) . For the OPRA exam, candidates must demonstrate a deep understanding of empirical antibiotic selections, clinical decision-making, and the application of Antimicrobial Stewardship (AMS) principles. AMS aims to optimize patient outcomes, minimize drug toxicity, and curb the emergence of antimicrobial resistance by restricting broad-spectrum agents.
1. Principles of Antimicrobial Stewardship (AMS)
AMS is a systematic approach to optimizing antimicrobial use. In Australian healthcare settings, this involves multidisciplinary teams implementing several key strategies:
Formulary Restriction and Approval Systems: Antibiotics are often categorized using a traffic light system to restrict broad-spectrum or "last-resort" agents:
Green (Unrestricted): Narrow-spectrum agents with low resistance potential (e.g., benzylpenicillin, amoxicillin).
Orange (Restricted): Requires clinical indication or local approval (e.g., ceftriaxone, ciprofloxacin).
Red (Highly Restricted): Requires infectious disease (ID) or clinical microbiologist approval (e.g., meropenem, linezolid, piperacillin-tazobactam).
Intravenous-to-Oral Switch (IVOS): Transitioning from IV to oral therapy as soon as clinical criteria are met to reduce catheter-related infections, hospital length of stay, and costs.
IVOS Criteria: Clinical improvement, afebrile for >24 hours, functioning gastrointestinal tract, no vomiting/diarrhoea, and no high-risk conditions requiring prolonged IV therapy (e.g., endocarditis, meningitis, osteomyelitis, undrained abscesses, or severe sepsis).
Therapeutic Drug Monitoring (TDM): Essential for aminoglycosides (gentamicin) and glycopeptides (vancomycin) to ensure efficacy and prevent nephrotoxicity/ototoxicity.
2. Respiratory Tract Infections (RTIs)
Empirical therapy for respiratory infections depends on severity assessment. In Australia, the CORB (Confusion, Oxygenation, Respiratory rate, Blood pressure) score or SMART-COP tool is used to assess Community-Acquired Pneumonia (CAP) severity.
Community-Acquired Pneumonia (CAP)
Severity Definition/Clinical Indicators First-Line Empirical Regimen (Adult) Atypical Coverage / Hypersensitivity Alternatives
Mild CORB score < 2; patient can be managed in the community. Amoxicillin 1 g orally, 8-hourly for 5 to 7 days. If atypical suspected (e.g., Mycoplasma pneumoniae ): Add doxycycline 100 mg orally, 12-hourly or clarithromycin 500 mg orally, 12-hourly .; If severe penicillin allergy: Doxycycline 100 mg orally, 12-hourly .
Moderate CORB score 2; requires hospital admission. Benzylpenicillin 1.2 g IV, 6-hourly AND doxycycline 100 mg orally (or IV), 12-hourly OR amoxicillin 1 g orally, 8-hourly AND doxycycline 100 mg orally, 12-hourly . If doxycycline is contraindicated: Replace with clarithromycin 500 mg orally, 12-hourly .; If severe penicillin allergy: Ceftriaxone 1–2 g IV daily (if cephalosporin is safe) or moxifloxacin 400 mg orally daily .
Severe CORB score ≥ \ge ≥ 3; requires ICU/HDU admission. Ceftriaxone 2 g IV, daily AND azithromycin 500 mg IV, daily . To cover Legionella and S. pneumoniae .; If severe penicillin/cephalosporin allergy: Moxifloxacin 400 mg IV, daily + gentamicin (if Gram-negative sepsis suspected).
Acute Bronchitis and Pharyngitis
Acute Bronchitis: Typically viral. Antibiotics are not recommended routinely unless the patient is systemically unwell or at high risk of complications (e.g., severe chronic lung disease).
Acute Pharyngitis/Tonsillitis: Mostly viral. Antibiotic treatment is reserved for patients at high risk of acute rheumatic fever (e.g., Aboriginal and Torres Strait Islander peoples living in rural/remote areas) or those meeting ≥ \ge ≥ 3 Centor criteria. First-line is phenoxymethylpenicillin (Penicillin V) 500 mg orally, 12-hourly for 10 days (crucial for eradicating Group A Streptococcus and preventing rheumatic fever).
3. Urinary Tract Infections (UTIs)
Urinary tract infections require differentiation between cystitis (lower UTI) and pyelonephritis (upper UTI), as well as special patient groups (pregnancy, renal impairment).
Uncomplicated Cystitis (Non-pregnant Females)
First-Line Options:
Trimethoprim 300 mg orally, daily at night for 3 days .
Nitrofurantoin 100 mg orally, 6-hourly (or 50 mg 6-hourly) for 5 days .
Cefalexin 500 mg orally, 12-hourly for 5 days .
Renal Impairment Warning: Nitrofurantoin requires an eGFR ≥ \ge ≥ 30 mL/min to achieve therapeutic concentrations in the urine. Below this level, it is ineffective and carries an increased risk of peripheral neuropathy and pulmonary toxicity. Trimethoprim should be avoided if eGFR < 15 mL/min.
Pregnancy Cystitis: First-line is cefalexin 500 mg orally, 12-hourly for 5 days or nitrofurantoin 100 mg orally, 6-hourly for 5 days .
Contraindications in Pregnancy: Trimethoprim is a folate antagonist and is contraindicated in the first trimester due to neural tube defect risks. Nitrofurantoin must be avoided at term ( 36+ weeks ) due to the risk of neonatal haemolytic anaemia (immature glutathione system).
Acute Pyelonephritis (Mild-to-Moderate)
Managed orally if tolerated: Cefalexin 1 g orally, 6-hourly for 10–14 days or amoxicillin/clavulanate 500/125 mg orally, 8-hourly for 10–14 days .
Severe pyelonephritis requires IV therapy: Gentamicin IV (single daily dose adjusted for renal function) + ampicillin 2 g IV, 6-hourly .
4. Skin and Soft Tissue Infections (SSTIs)
Empirical therapy must cover Staphylococcus aureus (including MRSA) and Streptococcus pyogenes (Group A Streptococcus).
Cellulitis (Mild/Moderate, Non-purulent):
First-line: Flucloxacillin 500 mg to 1 g orally, 6-hourly for 5 to 10 days . Flucloxacillin requires empty stomach administration (1 hour before or 2 hours after food) for optimal absorption.
Penicillin hypersensitivity (mild): Cefalexin 500 mg to 1 g orally, 6-hourly .
Penicillin hypersensitivity (severe/anaphylaxis): Clindamycin 300 mg to 450 mg orally, 8-hourly .
Impetigo:
Localized (few lesions): Topical mupirocin 2% ointment, 8-hourly for 5 days .
Widespread or multiple lesions: Oral flucloxacillin or cefalexin for 5 days.
5. Surgical Prophylaxis
The goal of surgical prophylaxis is to reduce the risk of surgical site infections (SSIs) by establishing bactericidal drug levels in tissue at the time of surgical incision.
Drug Choice: Cephazolin IV (first-generation cephalosporin) is the standard agent for most surgeries (cardiac, orthopaedic, gastrointestinal) because of its Gram-positive efficacy, long half-life, and safety.
Anaerobic coverage: In colorectal surgery, metronidazole IV is added.
Dosing and Timing:
Standard dose is cephazolin 2 g IV (or 3 g IV for patients weighing > 120 kg).
Must be administered within 60 minutes prior to surgical incision (ideally during induction of anaesthesia). If administered too early (>120 minutes) or after incision, SSI rates rise.
Intraoperative Redosing: Required if the procedure exceeds 4 hours from the first dose (due to cephazolin's half-life of 2 hours) or if there is major blood loss (> 1.5 litres).
Post-operative Duration: Single pre-operative doses are usually sufficient. Prophylaxis should never exceed 24 hours post-operatively; prolonged use increases resistance and Clostridioides difficile risk without reducing infections.